CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
CytoDyn announced the first patient has been dosed in the SALIENT-AD Phase 2a study, a collaboration with Weill Cornell Medicine evaluating leronlimab in Alzheimer’s disease. The open-label proof-of-concept study will enroll 10 to 20 patients over age 50 with early-stage, biomarker-confirmed Alzheimer’s, receiving weekly subcutaneous injections for 12 weeks. The primary endpoint assesses changes in brain inflammation and microglial activation using PET imaging, while secondary endpoints include safety, cognitive assessments, and blood-based biomarkers.
Key figures
- Drug Name
- leronlimab
- Phase Of Trial
- Phase 2a
- Patient count
- 10 to 20
- Treatment duration
- 12 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.